(Q40135352)

English

Combination immunotherapy with anti-CD20 and anti-HLA-DR monoclonal antibodies induces synergistic anti-lymphoma effects in human lymphoma cell lines

scientific article published on May 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

17 September 2017

Combination immunotherapy with anti-CD20 and anti-HLA-DR monoclonal antibodies induces synergistic anti-lymphoma effects in human lymphoma cell lines (English)

1 reference

Europe PubMed Central

17 September 2017

1 reference

based on heuristic

inferred from title

author name string

Evan Tobin

1

1 reference

Europe PubMed Central

17 September 2017

Gerald Denardo

2

1 reference

Europe PubMed Central

17 September 2017

Nan Zhang

3

1 reference

Europe PubMed Central

17 September 2017

Alan L Epstein

4

1 reference

Europe PubMed Central

17 September 2017

Cathy Liu

5

1 reference

Europe PubMed Central

17 September 2017

Sally Denardo

6

1 reference

Europe PubMed Central

17 September 2017

publication date

1 May 2007

1 reference

Europe PubMed Central

17 September 2017

Leukemia & Lymphoma

1 reference

Europe PubMed Central

17 September 2017

48

1 reference

Europe PubMed Central

17 September 2017

5

1 reference

Europe PubMed Central

17 September 2017

944-956

1 reference

Europe PubMed Central

17 September 2017

Final analysis of the ECOG I-COPA trial (E6484) in patients with non-Hodgkin's lymphoma treated with interferon alfa (IFN-alpha2a) plus an anthracycline-based induction regimen

1 reference

https://api.crossref.org/works/10.1080%2F10428190701272272

21 January 2018

Monoclonal antibody therapy of B cell lymphoma

1 reference

https://api.crossref.org/works/10.1080%2F10428190701272272

21 January 2018

Monoclonal antibodies as therapeutic agents for cancer

1 reference

https://api.crossref.org/works/10.1080%2F10428190701272272

21 January 2018

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

1 reference

https://api.crossref.org/works/10.1080%2F10428190701272272

21 January 2018

Growth inhibition of CD20-positive B lymphoma cell lines by IDEC-C2B8 anti-CD20 monoclonal antibody

1 reference

https://api.crossref.org/works/10.1080%2F10428190701272272

21 January 2018

Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance

1 reference

https://api.crossref.org/works/10.1080%2F10428190701272272

21 January 2018

Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy

1 reference

https://api.crossref.org/works/10.1080%2F10428190701272272

21 January 2018

Immunochemotherapy in indolent non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1080%2F10428190701272272

21 January 2018

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1080%2F10428190701272272

21 January 2018

Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin.

1 reference

https://api.crossref.org/works/10.1080%2F10428190701272272

21 January 2018

Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone.

1 reference

https://api.crossref.org/works/10.1080%2F10428190701272272

21 January 2018

Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs

1 reference

https://api.crossref.org/works/10.1080%2F10428190701272272

21 January 2018

Rituximab dose-escalation trial in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1080%2F10428190701272272

21 January 2018

A phase 1a clinical trial of LYM-1 monoclonal antibody serotherapy in patients with refractory B cell malignancies

1 reference

https://api.crossref.org/works/10.1080%2F10428190701272272

21 January 2018

Antilymphoma effects of anti-HLA-DR and CD20 monoclonal antibodies (Lym-1 and Rituximab) on human lymphoma cells.

1 reference

https://api.crossref.org/works/10.1080%2F10428190701272272

21 January 2018

Humanization and characterization of the anti-HLA-DR antibody 1D10.

1 reference

https://api.crossref.org/works/10.1080%2F10428190701272272

21 January 2018

MHC class II isotype-specific signaling complex on human B cells

1 reference

https://api.crossref.org/works/10.1080%2F10428190701272272

21 January 2018

Critical Lym-1 binding residues on polymorphic HLA-DR molecules

1 reference

https://api.crossref.org/works/10.1080%2F10428190701272272

21 January 2018

Lineage-related susceptibility of human hemopoietic cell lines to apoptosis.

1 reference

https://api.crossref.org/works/10.1080%2F10428190701272272

21 January 2018

Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1080%2F10428190701272272

21 January 2018

Levels of expression of CD19 and CD20 in chronic B cell leukaemias

1 reference

https://api.crossref.org/works/10.1080%2F10428190701272272

21 January 2018

Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia.

1 reference

https://api.crossref.org/works/10.1080%2F10428190701272272

21 January 2018

Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity

1 reference

https://api.crossref.org/works/10.1080%2F10428190701272272

21 January 2018

Rapid redistribution of CD20 to a low density detergent-insoluble membrane compartment

1 reference

https://api.crossref.org/works/10.1080%2F10428190701272272

21 January 2018

Clustered CD20 induced apoptosis: src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis

1 reference

https://api.crossref.org/works/10.1080%2F10428190701272272

21 January 2018

Lipid raft-dependent and -independent signaling through HLA-DR molecules

1 reference

https://api.crossref.org/works/10.1080%2F10428190701272272

21 January 2018

A recombinant bispecific single-chain Fv antibody against HLA class II and FcgammaRIII (CD16) triggers effective lysis of lymphoma cells

1 reference

https://api.crossref.org/works/10.1080%2F10428190701272272

21 January 2018

Intracellular Phosphotyrosine Induction by Major Histocompatibility Complex Class II Requires Co-aggregation with Membrane Rafts

1 reference

https://api.crossref.org/works/10.1080%2F10428190701272272

21 January 2018

Identifiers

10.1080/10428190701272272

1 reference

Europe PubMed Central

17 September 2017

1 reference

Europe PubMed Central

17 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40135352&oldid=1886489313"